Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström’s macroglobulinemia.
Bertrand E et al. Oncotarget. 2017 Dec 4;8(68):112917-112927. doi: 10.18632/oncotarget.22872. eCollection 2017 Dec 22.

Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
Kyle RA et al. N Engl J Med. 2018 Jan 18;378(3):241-249. doi: 10.1056/NEJMoa1709974.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.
Caers J et al. J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1.

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
Jurczyszyn A et al. Br J Haematol. 2018 Jan 7. doi: 10.1111/bjh.15092. [Epub ahead of print].

Rapid hematological responses improve outcomes in patients with very advanced (Stage IIIb) cardiac immunoglobulin light chain amyloidosis.
Manwani R et al. Haematologica. 2018 Jan 5. pii: haematol.2017.178095. doi: 10.3324/haematol.2017.178095. [Epub ahead of print].

Extramedullary plasmacytoma: rare neoplasm of parotid gland.
Abrar S et al. BMJ Case Rep. 2018 Jan 4;2018. pii: bcr-2017-222367. doi: 10.1136/bcr-2017-222367.

Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.
Thorsteinsdottir S et al. Blood Adv. 2017 Dec 21;1(27):2790-2798. doi: 10.1182/bloodadvances.2017010454. eCollection 2017 Dec 26.

Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis.
Sidana S et al. Bone Marrow Transplant. 2017 Dec 21. doi: 10.1038/s41409-017-0020-5. [Epub ahead of print].